PPARs: A Double-Edged Sword in Cancer Therapy?

Published Special Issues
1 September 2008
18 June 2024

This issue is now published.

Editors

Guest Editors

Dipak Panigrahy1 | Arja Kaipainen2 | Mark Kieran3 | Judah Folkman4 | Sui Huang5

1Harvard Medical School, USA

2Harvard Medical School, USA

3Harvard Medical School, USA

4Harvard Medical School, USA

5Harvard Medical School, USA

Export Citation(s)Download PDF(s)

Retraction
Open Access

Retracted: Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms

PPAR Research , 

Editorial
Open Access

PPARs: A Double-Edged Sword in Cancer Therapy?

Dipak Panigrahy,  Arja Kaipainen,  Mark W. Kieran,  Sui Huang, 
Review Article
Open Access

Combination Therapy of PPARγ Ligands and Inhibitors of Arachidonic Acid in Lung Cancer

Jordi Tauler,  James L. Mulshine, 
Review Article
Open Access

The Role of NF-κB in PPARα-Mediated Hepatocarcinogenesis

Howard P. Glauert,  Karen Calfee-Mason,  Yixin Li,  Vani Nilakantan,  Michelle L. Twaroski,  Job Tharappel,  Brett T. Spear, 
Review Article
Open Access

The Role of PPARγ Receptors and Leukotriene B4 Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer

Thomas E. Adrian,  Rene Hennig,  Helmut Friess,  Xianzhong Ding, 
Review Article
Open Access

PPARs Mediate Lipid Signaling in Inflammation and Cancer

Liliane Michalik,  Walter Wahli, 
Review Article
Open Access

Clinical Use of PPARγ Ligands in Cancer

Jennifer L. Hatton,  Lisa D. Yee, 
Review Article
Open Access

PPARγ, PTEN, and the Fight against Cancer

Rosemary E. Teresi,  Kristin A. Waite, 
Review Article
Open Access

The Role of PPARs in the Endothelium: Implications for Cancer Therapy

David Bishop-Bailey,  Karen E. Swales, 
Review Article
Open Access

PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments

Dorina Veliceasa,  Frank Thilo Schulze-Hoëpfner,  Olga V. Volpert, 
Review Article
Open Access

Potential Therapeutic Use of PPARγ-Programed Human Monocyte-Derived Dendritic Cells in Cancer Vaccination Therapy

Adrienn Gyöngyösi,  László Nagy, 
Review Article
Open Access

The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer

Kimberly A. Placzkowski,  Honey V. Reddi,  Stefan K. G. Grebe,  Norman L. Eberhardt,  Bryan McIver, 
Research Article
Open Access

[Retracted] Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms

Qing He,  Ruiping Pang,  Xin Song,  Jie Chen,  Huixin Chen,  Baili Chen,  Pinjin Hu,  Minhu Chen, 
Review Article
Open Access

PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion

Sebastian Seufert,  Roland Coras,  Christian Tränkle,  Darius P. Zlotos,  Ingmar Blümcke,  Lars Tatenhorst,  Michael T. Heneka,  Eric Hahnen, 
Review Article
Open Access

To Live or to Die: Prosurvival Activity of PPARγ in Cancers

Y. Lynn Wang,  Qi Miao, 
Review Article
Open Access

PPARγ: The Portrait of a Target Ally to Cancer Chemopreventive Agents

Ioannis Sainis,  Katerina Vareli,  Vasilios Karavasilis,  Evangelos Briasoulis, 
Review Article
Open Access

Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types

Jack D. Burton,  David M. Goldenberg,  Rosalyn D. Blumenthal, 
Review Article
Open Access

CXCR4 in Cancer and Its Regulation by PPARγ

Cynthia Lee Richard,  Jonathan Blay, 
Review Article
Open Access

PPARα- and DEHP-Induced Cancers

Yuki Ito,  Tamie Nakajima, 
Review Article
Open Access

The Role of PPARγ in the Cyclooxygenase Pathway in Lung Cancer

Saswati Hazra,  Katherine A. Peebles,  Sherven Sharma,  Jenny T. Mao,  Steven M. Dubinett,